Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

Health Canada approves INVOKAMET™ for the treatment of adults with type 2 diabetes Français Français


News provided by

Janssen Inc.

Jul 20, 2016, 07:00 ET

Share this article

Share toX

Share this article

Share toX

TORONTO, July 20, 2016 /CNW/ - Janssen Inc. announced today that INVOKAMET™, a twice daily fixed-dose therapy combining INVOKANA® (canagliflozin) and metformin hydrochloride into a single tablet, for the treatment of adults with type 2 diabetes is now available in Canada.1

INVOKANA® is the first sodium glucose co-transporter 2 (SGLT2) inhibitor approved in Canada that works with the kidney to promote the loss of glucose in the urine. Metformin, which is commonly prescribed early in the treatment of type 2 diabetes, decreases the production of glucose in the liver and improves the body's response to insulin.2

"By combining two proven therapies, INVOKAMET™ reduces the number of tablets people living with type 2 diabetes take each day," said Dr. Ronald Goldenberg, endocrinologist, LMC Diabetes & Endocrinology.* "Clinical trials show INVOKAMET™ helps lower blood sugar and is associated with a low risk of hypoglycemia. It can also provide a reduction in body weight and systolic blood pressure, which are important treatment goals for this patient population."

INVOKAMET™ is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.3 It should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis (DKA).4 INVOKAMET™ was approved by Health Canada on June 1, 2016.

ABOUT TYPE 2 DIABETES

Type 2 diabetes is a disease in which the pancreas does not produce enough insulin and/or the body does not properly use the insulin it makes. As a result, glucose builds up in the blood instead of being used for energy.5 If left untreated or improperly managed, diabetes can result in a variety of complications, including heart disease, kidney disease, eye disease and nerve damage.6

Of the three million Canadians living with diabetes, 90 per cent have been diagnosed with type 2 diabetes.7 By 2025, it is estimated that the number of Canadians with diabetes will grow to more than four million.8

CLINICAL TRIAL PROGRAM

Study results demonstrated administration of INVOKAMET™ was equivalent to co-administration of corresponding doses of INVOKANA® and metformin as individual tablets.9 The co-administration of INVOKANA® and metformin has been studied in six Phase 3 clinical studies that enrolled 5,031 patients with type 2 diabetes.10 The Phase 3 studies evaluated INVOKANA® in combination with metformin, compared to metformin alone or to metformin plus another diabetes therapy. The studies were part of the comprehensive global Phase 3 program for INVOKANA® that enrolled 10,285 patients, one of the largest clinical programs in type 2 diabetes submitted to health authorities to date.11 The Phase 3 studies showed the combination of INVOKANA® and metformin lowered blood sugar and in pre-specified secondary endpoints, was associated with significant reductions in body weight and systolic blood pressure.12

In two studies comparing INVOKANA® plus metformin to current standard treatments plus metformin — one studying sitagliptin and the other studying glimepiride — INVOKANA® dosed at 300 mg provided greater reductions in A1C levels and body weight than either comparator.13 A1C is the per cent of red blood cell hemoglobin with glucose attached to it and an indicator of average blood glucose concentration over the previous two to three months.14 In the two studies, the overall incidence of adverse events was similar with INVOKANA® and the comparators.15

Common side effects reported for INVOKANA® include vaginal yeast infection, rash or redness of the penis or foreskin, urinary tract infection, increased urination, constipation, nausea and feeling thirsty. Common side effects reported for metformin are diarrhea, excess gas, abdominal discomfort, nausea/vomiting and indigestion.16

Lactic acidosis is a rare, but serious, metabolic complication that can occur due to metformin accumulation during treatment with INVOKAMET™.17 This is more common in people whose kidneys are not working properly. As well, clinical trial cases of diabetic ketoacidosis, a serious life-threatening condition requiring urgent hospitalization, have been reported in patients with type 1 and type 2 diabetes mellitus treated with SGLT2 inhibitors, including INVOKANA®.18 Hypoglycemia does not occur in patients receiving metformin alone under usual circumstances of use.19 INVOKANA® can increase the risk of hypoglycemia when combined with insulin or a medication that increases insulin levels (e.g., a sulfonylurea). Therefore, a lower dose of insulin or insulin-raising medication may be required to minimize the risk of hypoglycemia when used in combination with INVOKAMET™.20

ABOUT INVOKANA®

INVOKANA® was approved by Health Canada on May 23, 2014. The treatment is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. INVOKANA® is currently approved as a single agent in 70 countries.

ABOUT THE JANSSEN PHARMACEUTICAL COMPANIES

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com/canada. Follow us at @JanssenCanada.

*Dr. Goldenberg was not compensated for any media work. He has been a paid consultant to Janssen Inc.

REFERENCES
__________________________
1 INVOKAMET™ Product Monograph, Janssen Inc., June 1, 2016.
2 INVOKAMET™ Product Monograph, Janssen Inc., June 1, 2016.
3 INVOKAMET™ Product Monograph, Janssen Inc., June 1, 2016.
4 INVOKAMET™ Product Monograph, Janssen Inc., June 1, 2016.
5 Canadian Diabetes Association. Types of Diabetes. Available at: http://www.diabetes.ca/about-diabetes/types-of-diabetes. Accessed April 19, 2016.
6 Canadian Diabetes Association. Types of Diabetes. Available at: http://www.diabetes.ca/about-diabetes/types-of-diabetes. Accessed April 19, 2016.
7 Canadian Diabetes Association. Diabetes Fact Sheet. Available at: http://www.diabetes.ca/files/Diabetes_Fact_Sheet.pdf. Accessed April 20, 2016.
8 Canadian Diabetes Association. 2015 Report on Diabetes: Driving Change. Toronto, ON: CDA; 2015.
9 INVOKAMET™ Product Monograph, Janssen Inc., June 1, 2016.
10 INVOKAMET™ Product Monograph, Janssen Inc., June 1, 2016.
11 INVOKAMET™ Product Monograph, Janssen Inc., June 1, 2016.
12 INVOKAMET™ Product Monograph, Janssen Inc., June 1, 2016.
13 INVOKAMET™ Product Monograph, Janssen Inc., June 1, 2016.
14 INVOKAMET™ Product Monograph, Janssen Inc., June 1, 2016.
15 INVOKAMET™ Product Monograph, Janssen Inc., June 1, 2016.
16 INVOKAMET™ Product Monograph, Janssen Inc., June 1, 2016.
17 INVOKAMET™ Product Monograph, Janssen Inc., June 1, 2016.
18 INVOKANA® Product Monograph, Janssen Inc., June 2, 2016
19 INVOKAMET™ Product Monograph, Janssen Inc., June 1, 2016.
20 INVOKAMET™ Product Monograph, Janssen Inc., June 1, 2016.

SOURCE Janssen Inc.

Media Contact: Jennifer McCormack, Office: (416) 382-5121; Investor Contact: Lesley Fishman, Office: (732) 524-3922

Modal title

Organization Profile

Janssen Inc.

    Also from this source

  • Health Canada authorizes LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer

  • Johnson & Johnson champions first-ever Canadian consensus paper identifying critical gaps in psoriasis care for patients with skin of colour

  • RYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision company.